DOI: 10.26686/wgtn.23639313
|View full text |Cite
|
Sign up to set email alerts
|

Investigating the effects of Kappa opioid receptor agonists on remyelination in a preclinical model of multiple sclerosis

Abstract: <p>Multiple sclerosis (MS) is a heterogeneous and debilitating neurodegenerative disease of the central nervous system, characterised by chronic inflammation and demyelination. MS is estimated to affect 2.5 million people worldwide and results in motor, sensory, autonomic and cognitive disabilities. There is currently no cure for MS, and the immunomodulatory therapies available are limited in their efficacy to decelerate disability progression. This disease continues to bear a heavy burden on its affecte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 244 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?